Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.

doi:10.1158/1078-0432.CCR-21-0885

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.

Clinical cancer research : an official journal of the American Association for Cancer Research - 13 May 2022

LeNoue-Newton Michele L, Chen Sheau-Chiann, Stricker Thomas, Hyman David M, Blauvelt Natalie, Bedard Philippe L, Meric-Bernstam Funda, Punglia Rinaa S, Schrag Deborah, Lepisto Eva M, Andre Fabrice, Smyth Lillian, Dogan Semih, Yu Celeste, Wathoo Chetna, Levy Mia, Eli Lisa D, Xu Feng, Mann Grace, Lalani Alshad S, Ye Fei, Micheel Christine M, Arnedos Monica

Abstract excerpt

PURPOSE: We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor-positive advanced breast cancer tumors harboring an ERBB2 mutation in the absence of a HER2 amplification. EXPERIMENTAL DESIGN: We retrospectively collected information from the American Association of Cancer Research-Genomics Evidence Neoplasia Information Exchange registry database from patients with hormone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Carcinoma, Lobular

Share to Case-Control Studies

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Share to Recurrence

Source

Open in PubMed

Identifiers

PMID: 35190802
DOI: 10.1158/1078-0432.CCR-21-0885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.PMID 35190802Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).Semantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

Combined Hormone Receptor and Human Epidermal Growth Factor Receptor-2 Expression Reflects Inter-and Intra-tumor Heterogeneity in Hormone Receptor-positive/human Epidermal Growth Factor Receptor-2-positive Breast CancerSemantic proximity Read ↗

The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors.Semantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.Semantic proximity Read ↗

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.Semantic proximity Read ↗

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.Semantic proximity Read ↗

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read ↗

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various CancersSemantic proximity Read ↗

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.